DE69925928D1 - Verwendung einer sich an periphere benzodiazepinrezeptoren bindenden substanz zur behandlung von hautstress - Google Patents

Verwendung einer sich an periphere benzodiazepinrezeptoren bindenden substanz zur behandlung von hautstress

Info

Publication number
DE69925928D1
DE69925928D1 DE69925928T DE69925928T DE69925928D1 DE 69925928 D1 DE69925928 D1 DE 69925928D1 DE 69925928 T DE69925928 T DE 69925928T DE 69925928 T DE69925928 T DE 69925928T DE 69925928 D1 DE69925928 D1 DE 69925928D1
Authority
DE
Germany
Prior art keywords
treatment
crop
peripheral benzodiazepine
substance binding
benzodiazepine receptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69925928T
Other languages
English (en)
Other versions
DE69925928T2 (de
Inventor
Pierre Casellas
Jean-Marie Derocq
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Application granted granted Critical
Publication of DE69925928D1 publication Critical patent/DE69925928D1/de
Publication of DE69925928T2 publication Critical patent/DE69925928T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/70—Biological properties of the composition as a whole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/803—Physical recovery methods, e.g. chromatography, grinding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/886—Streptomyces

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE69925928T 1998-11-17 1999-11-10 Verwendung einer sich an periphere benzodiazepinrezeptoren bindenden substanz zur behandlung von hautstress Expired - Fee Related DE69925928T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9814387A FR2785803B1 (fr) 1998-11-17 1998-11-17 Utilisation d'une substance se liant au recepteur peripherique des benzodiazepines dans le traitement des stress cutanes
FR9814387 1998-11-17
PCT/FR1999/002761 WO2000028947A2 (fr) 1998-11-17 1999-11-10 Utilisation d'une substance se liant au recepteur peripherique des benzodiazepines dans le traitement des stress cutanes

Publications (2)

Publication Number Publication Date
DE69925928D1 true DE69925928D1 (de) 2005-07-28
DE69925928T2 DE69925928T2 (de) 2006-08-17

Family

ID=9532791

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69925928T Expired - Fee Related DE69925928T2 (de) 1998-11-17 1999-11-10 Verwendung einer sich an periphere benzodiazepinrezeptoren bindenden substanz zur behandlung von hautstress

Country Status (18)

Country Link
US (2) US6767533B1 (de)
EP (1) EP1131039B1 (de)
JP (1) JP2002529486A (de)
KR (1) KR20010089475A (de)
AT (1) ATE298230T1 (de)
AU (1) AU764786B2 (de)
CA (1) CA2349919A1 (de)
CY (1) CY1105144T1 (de)
DE (1) DE69925928T2 (de)
DK (1) DK1131039T3 (de)
ES (1) ES2244246T3 (de)
FR (1) FR2785803B1 (de)
HK (1) HK1037966A1 (de)
HR (1) HRP20010367A2 (de)
HU (1) HUP0105058A2 (de)
PT (1) PT1131039E (de)
SI (1) SI1131039T1 (de)
WO (1) WO2000028947A2 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1140106B1 (de) * 1998-12-18 2005-08-03 Scios Inc. Behandlung von erkrankungen mit zystenbildung
US20060025388A1 (en) 1999-04-30 2006-02-02 Glick Gary D Compositions and methods relating to novel compounds and targets thereof
US7276348B2 (en) * 1999-04-30 2007-10-02 Regents Of The University Of Michigan Compositions and methods relating to F1F0-ATPase inhibitors and targets thereof
US20050113460A1 (en) * 1999-04-30 2005-05-26 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US7572788B2 (en) * 1999-04-30 2009-08-11 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US20030119029A1 (en) * 1999-04-30 2003-06-26 Regents Of The University Of Michigan Compositions and methods relating to novel benzodiazepine compounds and targets thereof
US20040176358A1 (en) * 1999-04-30 2004-09-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
ATE258439T1 (de) * 1999-04-30 2004-02-15 Univ Michigan Verwendung von benzodiazepinen zur behandlung von apoptose-induzierten autoimmunerkrankungen
DE10021468A1 (de) * 2000-05-04 2001-11-08 Basf Ag Verwendung von PARP-Inhibitoren in kosmetischen Zubereitungen
US7582624B2 (en) 2002-09-20 2009-09-01 Arrow Therapeutics Limited Benzodiazepine derivatives and pharmaceutical compositions containing them
US20050272723A1 (en) * 2004-04-27 2005-12-08 The Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
US20060052369A1 (en) * 2004-09-07 2006-03-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
WO2006067327A2 (fr) * 2004-12-20 2006-06-29 L'oreal Antagonistes des recepteurs peripheriques des benzodiazepines pour le traitement des peaux seches
FR2879450B1 (fr) * 2004-12-20 2007-02-09 Oreal Antagonistes des recepteurs peripheriques des benzodiazepines pour le traitement des peaux seches
FR2879451B1 (fr) * 2004-12-20 2007-05-04 Oreal Utilisation de ligands du recepteur des benzodiazepines pour lutter contre les signes du vieillissement
BRPI0517216A (pt) * 2004-12-20 2008-09-30 Oreal uso cosmético de pelo menos um antagonista dos receptores periféricos das benzodizepinas e processo cosmético para combater as rugas ou as rìdulas
JP2008528448A (ja) 2005-01-03 2008-07-31 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 新規化合物に関連する組成物および方法、ならびにその標的
EP1893218A4 (de) 2005-06-01 2011-01-12 Univ Michigan Ungelöste benzodiazepin-zusammensetzungen und verfahren
CA2628193C (en) 2005-11-01 2012-08-14 The Regents Of The University Of Michigan Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties
KR20070058291A (ko) * 2005-12-02 2007-06-08 엘지전자 주식회사 기록매체, 기록매체의 관리정보 기록방법 및 기록장치
US7759338B2 (en) * 2006-04-27 2010-07-20 The Regents Of The University Of Michigan Soluble 1,4 benzodiazepine compounds and stable salts thereof
WO2007146167A1 (en) 2006-06-09 2007-12-21 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
EP2059813A2 (de) * 2006-06-26 2009-05-20 Technion Research & Development Foundation LTD. Verfahren und kits zur krebsdiagnose
US7851465B2 (en) 2007-03-09 2010-12-14 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
BRPI0815782A2 (pt) * 2007-08-31 2015-02-24 Archimedes Dev Ltd Composição para a dispensação intranasal de uma droga, uso de uma composição não aquosa, dispositivo para a dispensação nasal de drogas ou um cartucho de dose, usos de um veículo, não aquoso, e de uma droga de benzodiazepina e um veículo não aquoso
CN101855203B (zh) 2007-09-14 2014-03-19 密执安州立大学董事会 F1f0-atp合成酶抑制剂以及相关的方法
CN101918375A (zh) 2007-11-06 2010-12-15 密歇根大学董事会 在皮肤病症的治疗中有用的苯并二氮杂*酮化合物
AU2009291632B2 (en) 2008-09-11 2013-04-04 The Regents Of The University Of Michigan Aryl guanidine F1F0-ATPase inhibitors and related methods
WO2010121164A2 (en) 2009-04-17 2010-10-21 The Regents Of The University Of Michigan 1,4-benzodiazepinone compounds and their use in treating cancer
US9075060B2 (en) 2009-06-16 2015-07-07 Technion Research & Development Foundation Limited Methods for diagnosing oral or oral-pharyngeal cancer
US8673897B2 (en) 2009-09-18 2014-03-18 The Regents Of The University Of Michigan Benzodiazepinone compounds and methods of treatment using same
US9126978B2 (en) 2009-11-17 2015-09-08 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
ES2703752T3 (es) 2009-11-17 2019-03-12 Univ Michigan Regents 1,4-Benzodiazepina-2,5-dionas y compuestos relacionados que presentan propiedades terapéuticas

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5279082A (en) * 1975-12-25 1977-07-02 Green Cross Corp:The Preparation of anti-tumor compound
JPS5473195A (en) * 1977-11-22 1979-06-12 Takeda Chem Ind Ltd Preparation of tomaymycins
JPS56121495A (en) * 1980-02-29 1981-09-24 Kyowa Hakko Kogyo Co Ltd Preparation of benzodiazepine derivative
IL101387A (en) * 1992-03-26 1999-11-30 Pharmos Ltd Emulsion with enhanced topical and/or transdermal systemic effect utilizing submicron oil droplets
CA2141192C (en) * 1992-07-28 1999-02-02 Roberta C. Bloom Pharmaceutical composition for topical use containing a crosslinked cationic polymer and an alkoxylated ether
ATE258439T1 (de) * 1999-04-30 2004-02-15 Univ Michigan Verwendung von benzodiazepinen zur behandlung von apoptose-induzierten autoimmunerkrankungen

Also Published As

Publication number Publication date
FR2785803A1 (fr) 2000-05-19
KR20010089475A (ko) 2001-10-06
FR2785803B1 (fr) 2005-03-25
CY1105144T1 (el) 2010-03-03
JP2002529486A (ja) 2002-09-10
EP1131039B1 (de) 2005-06-22
HRP20010367A2 (en) 2002-06-30
US6767533B1 (en) 2004-07-27
DE69925928T2 (de) 2006-08-17
HK1037966A1 (en) 2002-03-01
EP1131039A2 (de) 2001-09-12
ATE298230T1 (de) 2005-07-15
SI1131039T1 (en) 2005-10-31
WO2000028947A3 (fr) 2000-08-03
HUP0105058A2 (hu) 2002-05-29
AU764786B2 (en) 2003-08-28
CA2349919A1 (en) 2000-05-25
DK1131039T3 (da) 2005-10-17
AU1166100A (en) 2000-06-05
WO2000028947A2 (fr) 2000-05-25
US20050090489A1 (en) 2005-04-28
ES2244246T3 (es) 2005-12-01
PT1131039E (pt) 2005-11-30

Similar Documents

Publication Publication Date Title
DE69925928D1 (de) Verwendung einer sich an periphere benzodiazepinrezeptoren bindenden substanz zur behandlung von hautstress
DE69816109D1 (de) Substituierte imidazole zur behandlung von entzündlichen krankheiten
DE69822919D1 (de) Spezifische Antikörper zur Verwendung in der Herstellung pharmazeutischer Zusammensetzungen nützlich für die Vorbeugung oder Behandlung von Gastritis, Magen- und Zwölffingerdarmgeschwüren
ATE122205T1 (de) Fungizide zusammensetzung zur behandlung von saatgut.
DE69710095D1 (de) Pharmazeutische zubereitung zur behandlung von diabetes
ATE90082T1 (de) Imidazol-verbindung und diese enthaltende biozide zusammensetzungen.
DE60031396D1 (de) Zubereitung zur behandlung von einer neurologischen erkrankung
DE69724016D1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen erkrankungen der atemwege
DE69319551D1 (de) Indolin Verbindungen zur Behandlung von Dysurien
DE122007000002I1 (de) Pharmazeutische Zubereitung zur Verwendung in der Behandlung von Diabetes.
ATE258919T1 (de) Verwendung von alkylierten iminozuckern zur behandlung von multipler medikamentenresistenz
DE3780972D1 (de) Verwendung von spezifischen n-methyl-d-aspartat-rezeptor-antagonisten zur praevention und behandlung von neurodegeneration.
DE69941154D1 (de) Verwendung von Hydroxamatverbindungen zur Behandlung von HER-2/neu positiven Karzinomen
DE69634951D1 (de) Topische verwendung von betulinsäure zur behandlung bösartiger melanome
EE9700225A (et) Meetod diabetes mellituse raviks, kasutades KKF
DE3777858D1 (de) Okulare antihypertensive zusammensetzung zur topischen verwendung.
DE69904922D1 (de) Pharmazeutische zusammensetzung zur behandlung von alkoholabhängigkeit, die opioid antagonisten mit nmda-rezeptorkomplex-modulatoren enthält
DE3882775D1 (de) Zusammensetzung zur behandlung von parodontaler krankheit.
DE69518037D1 (de) Klebstoffmischung für die Zahnbehandlung
DE69841984D1 (de) Zusammensetzung aus nanokapseln zur behandlung von intraarticulaeren erkrankungen
DE59706572D1 (de) Verwendung von carboxyamid-polysiloxanen zur lederhydrophobierung
DE3650647D1 (de) Arzneimittel zur Behandlung von Anxietas
DE69128941D1 (de) Verwendung von angiotensin-ii-rezeptorantagonisten in der behandlung der diabetischen nephropathie
ATE221763T1 (de) Die verwendung von glyceryltriacetat zur behandlung von onychomykosen
ATE210447T1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: PFENNING MEINIG & PARTNER GBR, 80339 MUENCHEN

8339 Ceased/non-payment of the annual fee